本文已被：浏览 3357次 下载 0次
中文摘要: 目的 观察利伐沙班治疗老年非瓣膜性房颤患者疗效及安全性。方法 选取复旦大学附属华东医院老年非瓣膜性房颤患者120例，根据随机数字表原则，将患者分为对照组和观察组，每组各60例。对照组采用华法林治疗，将国际标准化比值(INR)控制在1.8～2.5，观察组患者采用利伐沙班治疗。通过观察两组患者卒中或血栓事件发生率以比较治疗效果，通过观察两组患者出血事件发生率和肝肾功能变化以比较安全性。结果 两组患者卒中或血栓事件发生率比较差异无统计学意义(P＞0.05)。观察组患者出血事件发生率低于对照组，差异具有统计学意义(P＜0.05)。两组患者治疗前后肝肾功能指标比较，差异均无统计学意义(P＞0.05)。结论 利伐沙班在治疗老年非瓣膜性房颤患者中，具有确切的治疗效果，且安全性优于华法林。
Abstract:OBJECTIVE To observe the efficacy and safety of rivaroxaban in the treatment of elderly patients with non-valvular atrial fibrillation.METHODS A total of 120 elderly patients with non-valvular atrial fibrillation were selected and divided into control group and observation group, 60 cases in each group.The control group was treated with warfarin, the international standardized ratio(INR)was controlled at 1.8～2.5, the observation group patients treated with rivaroxaban.Stroke or thrombosis incidence rate were compared to analysis the therapeutic effect.Bleeding incidence and liver and kidney function changes were compared to analysis the safety. RESULTS There was no significant difference in the incidence of stroke or thrombosis between the two groups (P＞0.05).The incidence of bleeding in the observation group was lower than that in the control group, the difference was statistically significant(P＜0.05).Before and after treatment,there was no significant difference in theliver and kidney function indicators(P＞0.05).CONCLUSION Rivaroxaban has proven therapeutic efficacy in the treatment of elderly patients with NVAF and is superior to warfarin in safety.
文章编号：3201806033 中图分类号：R541.7+5 文献标志码：
基金项目:
| 作者 | 单位 |
| 何 菡①,贾明磊①＃,郭新贵① |
| Author Name | Affiliation |
引用文本：